PD-1 Knockout Could Be Caribou’s Key To Allo CAR-T Success
Early Response Rate Exceeds Competitors
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.